{{featured_button_text}}
Propeller Health

Propeller's platform of sensors has received FDA clearance for use with GSK's Ellipta inhaler.

Propeller Health has received clearance from the U.S. Food and Drug Administration to market its sensor platform along with the GSK (GlaxoSmithKline) Ellipta inhaler.

Propeller's customized medication sensor was developed with GSK as part of a collaboration between the two companies announced in December 2015. It will record the dates and times a patient with asthma or COPD (chronic obstructive pulmonary disease) uses the device and will send the data to GSK researchers to analyze.

"We hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trials," said Dave Allen, GSK's head of respiratory research and development.

It is the eighth FDA clearance for use of the Madison company's technology.

Propeller announced in October that it has received another $21.5 million from investors, including GSK's venture capital offshoot. That brings the company's total investor funding to $44.5 million. 

Founded in 2010, Propeller Health has 55 employees, about 40 of them in Madison. Its technology is being used in more than 45 programs around the U.S.

Capital W: Plug in to Wisconsin politics

Subscribe to our Politics email!

* I understand and agree that registration on or use of this site constitutes agreement to its user agreement and privacy policy.
0
0
0
0
0